Results 1 to 10 of about 17,315 (165)
Flavonoids as potential anti-asthmatic agents [PDF]
Frontiers in ImmunologyAsthma affects approximately 260 million people globally and causes an estimated 450,000 deaths annually, posing a serious threat to human health and life quality.
Zhuofen Deng +6 more
doaj +4 more sources
Antagonism of the Human Thromboxane A2 Receptor by an Anti-Asthmatic Agent AA-2414
Biological and Pharmaceutical Bulletin, 1994 The human thromboxane A2 receptor (TXA2-R)-coding gene was introduced into Chinese hamster ovary cells and a cell line (TCHO-25) stably expressing TXA2-R, at a level of 3 x 10(5)/cell, was obtained. An anti-asthmatic agent AA-2414 [(+-)-7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7- phenylheptanoic acid] competitively inhibited the specific binding of a ...
R Sasada, Y Ashida, Reiko Sasada
exaly +4 more sources
Does bronchial asthma influences dental health of the diseased children? [PDF]
Vojnosanitetski Pregled, 2022 Background/Aim. Asthma is a chronic inflammatory lung disorder. The effect of asthma drugs on oral health is still the subject of debate among researchers in dentistry.
Davidović Bojana +6 more
doaj +1 more source
Pharmacological Research, 2022 Asthma is a major respiratory disorder characterised by chronic inflammation and airway remodelling. It affects about 1–8% of the global population and is responsible for over 461,000 deaths annually.
Emmanuel Oshiogwe Okwuofu +3 more
doaj +1 more source
Perception of Illness and Fear of Inhaled Corticosteroid Use among Parents of Children with Asthma
Children, 2023 The most prevalent children’s chronic disease worldwide is asthma which has notable negative impacts on patients’ and parent’s quality of life. Daily inhaled corticosteroids (ICS) therapy is a preferred controller choice.
Jasna Petric Duvnjak +4 more
doaj +1 more source
Asthma Research and Practice, 2022 Background Adherence to inhaler medication is an important contributor to optimum asthma control along with adequate pharmacotherapy. The objective of the present study was to assess self-reported adherence levels and to identify the potential factors ...
Md. Abdur Rafi +16 more
doaj +1 more source
Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: Meta-analysis [PDF]
Vojnosanitetski Pregled, 2018 Background/Aim. Reslizumab is humanized monoclonal antibody produced by recombinant DNA technology which binds to circulating interleukin-5 (IL-5) and down-regulates the IL-5 signaling pathway. Reslizumab is indicated for the add-on maintenance treatment
Milosavljević Miloš N. +5 more
doaj +1 more source
Short-acting β2-agonist prescriptions in patients with asthma: findings from the South Korean cohort of SABINA III [PDF]
The Korean Journal of Internal MedicineBackground/Aims Despite short-acting β2-agonist (SABA) overuse being associated with poor asthma outcomes, data on SABA use in South Korea is scarce.
Kwang-Ha Yoo +6 more
doaj +1 more source
Plants, 2023 Plants of the genus Tylophora have commonly been used in traditional medicine in various communities, especially in the tropical and subtropical regions of climatic zones.
Ehab M. Mostafa +10 more
doaj +1 more source
Research on and developmental strategy of anti-asthmatic agents
Folia Pharmacologica Japonica, 2008 気管支喘息の基本となる病態が気道の慢性炎症であることから，吸入ステロイド薬を中心とした抗炎症療法の導入は喘息症状のコントロールを可能にし，喘息患者のquality of lifeを飛躍的に向上させた．その一方で，分子レベルでの病態への理解が深まり，特に気道炎症の発症・進展に関わる過程と関連する各種因子の解明が進むことで，より安全で効果的な治療薬の創製に向けた研究開発が試みられている．本稿では，気道炎症の制御を作用メカニズムとした新規喘息治療薬に焦点をあて，その概略を紹介する．
Totsuka, Ryuichi, Kikuchi, Matsuo
openaire +3 more sources